PMS2 mutation + MLH1 mutation	Gastric Cancer	PMS2 mutation + MLH1 mutation	Gastric Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PMS2 mutation + MLH1 mutation	Colorectal Cancer	PMS2 mutation + MLH1 mutation	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PMS2 mutation + MLH1 mutation	Prostate Cancer	PMS2 mutation + MLH1 mutation	Prostate Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4

PMS2 mutation + MLH1 mutation

Associations